234 075 111

Externí hodnocení kvality (SEKK, DAkkS, PREVECAL, SZÚ, INSTAND)

SEKK

AUTOIMUNITA

AIM 1/16   Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/16 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/17 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/17 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/18 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/18 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/19 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/19 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/20  Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/20 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/21 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/21 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/21-923 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/22 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/22-923 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/22 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

APLA

APLA 1/16 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 3/16  Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 1/17  Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 2/17 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 1/18 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 2/18 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 1/19 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 2/19 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 1/20 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 2/20 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 1/21 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 2/21 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 1/22 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 2/22 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

IGIT

IGIT 1/16 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 2/16 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 1/17 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 2/17  Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 1/18 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 2/18 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 1/19 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 2/19 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 1/20 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA

IGIT 2/20 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA

IGIT 1/21 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA

IGIT 2/21 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA

IGIT 1/22 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA

IGIT 2/22 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA

RF

RF 1/16  Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/16 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 1/17 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/17 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 1/18 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/18 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 1/19 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/19 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 1/20 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/20 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 1/21 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/21 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 1/22 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/22 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

PODTŘÍDY IgG

PIG/19 Podtřídy IgG (IgG 4)

PIG/20 Podtřídy IgG (IgG 4)

IFT

IFT 1/16  Imunofenotypizace

IFT 2/2016  Imunofenotypizace

IFT 1/2017  Imunofenotypizace

IFT 2/2017  Imunofenotypizace

IFT 1/2018  Imunofenotypizace

IFT 2/2018  Imunofenotypizace

IFT 1/2019  Imunofenotypizace

IFT 2/2019 Imunofenotypizace

IFT 1/2020 Imunofenotypizace

IFT 2/2020  Imunofenotypizace

IFT 1/2021 Imunofenotypizace

IFT 2/2021 Imunofenotypizace

IFT 2/2022 Imunofenotypizace

IFT 1/2023 Imunofenotypizace

PROTILÁTKY PROTI SARS-CoV-2

T 1/22 Protilátky proti SARS-CoV-2 (studie)



DAkkS

Hodnocení kvality DAkkS EuroImmun

QV1510-140325 Protilátky proti buněčným jádrům, Anti-dsDNA, Anti-nukleozomy, LIA

QV2132-140325   Anti- borrelia

QV1505-140513 Anti-CCP

QV1632-140513 anti-kardiolipin, anti-β2 glykoprotein

QV1913-140513-1 Anti-tTG, Anti-Endomysium, Anti-Gliadin

QV1913-140513-2  Anti-Gliadin

QV1200-140513-1 Protilátky proti granulocytům

QV1200-140513-2 Anti-MPO, Anti-PR3

QV2790-140325 Protilátky proti viru Epstein-Barrové

Hodnocení kvality DAkkS EuroImmun Lübeck

QV1510-220315 Ana 1/2022

QV2132-220315 Borrelia 1/2022

QV2606-220315 SARS-CoV-2 1/2022 

QV1530-220315 Myopathies 1/2022

QV2580-220315 Parvovirus 1/2022



PREVECAL



SZÚ - Státní zdravotní ústav



INSTAND

Immunophenotyping

IPT 2016

Instand IFT March 2015

Instand IFT March 2016

Instand IFT March 2017

Instand IFT March 2018

Instand IFT March 2019

Instand IFT September 2020

Instand IFT September 2021

Instand IFT September 2022

HLA

HLA 2015

Instand HLA B27 May2016

Instand HLA B27 Nov 2016

Instand HLA B27 April2017

Instand HLA B27 Nov 2017

Instand HLA B27 February 2018

Instand HLA B27 February 2019

Instand HLA B27 Nov 2019

Instand HLA B27 Nov 2020

Instand HLA B27 April 2021

Instand HLA B27 December 2021

Instand HLA B27 duben 2022

Instand HLA B27 December 2022

Istand_HLA B27 April 2023